[Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)].
Eight children aged between 4 and 16 years with thalassemia major were treated for 30 months with repeated transfusions and a chelating agent. Deferoxamine was given intravenously for 12 months and subcutaneously in the next 18 months. The results of urine iron concentrations, the practical difficulties of both routes of administration and the clinical results are presented. The therapeutic regime proposed is capable or reducing the iron overload.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007501:Iron / Q000506:poisoning*; D008297:Male; D013789:Thalassemia / Q000150:complications*
D007501:Iron; D003676:Deferoxamine
La desferrioxamine B: rôle et modalités d'utilisation dans le traitement de la surcharge martiale de la thalassémie majeure.